Satoshi Osawa

Dr. Satoshi Osawa

Department of Endoscopic and Photodynamic Medicine
orcid

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 March 2016 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
TKT. Kagami
T. Kagami
SSS. Sahara
S. Sahara
HIH. Ichikawa
H. Ichikawa
TUT. Uotani
T. Uotani
MYM. Yamade
M. Yamade
TFT. Furuta
T. Furuta

17 November 2015 in Journal of Crohn's and Colitis
Verified
Journal Article
Open access
PDF file
KIKentaro Ikeya
Kentaro Ikeya
HHHiroyuki Hanai
Hiroyuki Hanai
KSKen Sugimoto
Ken Sugimoto
SOSatoshi Osawa
Satoshi Osawa
SKShinsuke Kawasaki
Shinsuke Kawasaki
FWFumitoshi Watanabe
Fumitoshi Watanabe
The Ulcerative Colitis Endoscopic Index of Severity (UCEIS) and the Mayo endoscopic score (Mayo ES) are used to evaluate ulcerative colitis (UC) severity. This study compared UCEIS and the Mayo ES for evaluating UC severity and outcomes in patients undergoing remission induction during routine clinical practice with the aim of predicting medium- to long-term prognosis. Forty-one UC patients who received colonoscopy before and after tacrolimus remission induction therapy were included. An index of clinical activity and endoscopic findings scored by both the UCEIS and the Mayo ES were determined. Changes in UCEIS and Mayo ES before and after induction therapy were compared. The mean UCEIS improved from 6.2±0.9 to 3.4±2.1 ( p < 0.001). Based on the UCEIS, a significant reduction was reached in both the response and the remission groups. In contrast, the Mayo ES did not reflect a significant change in the response group. The discrepancy appeared to be due to ulcers becoming smaller and shallower during the early stages of mucosal healing; the Mayo ES seems to miss these early changes. In other words, whereas the UCEIS indicates improvements when ulcers shrink, the Mayo ES does not distinguish deep ulcers from shallow ulcers and is 3 (severe UC) for both deep and shallow ulcers. Additionally, better UCEIS strata after induction therapy were associated with lower incidences of colectomy ( p = 0.0001) or relapse ( p = 0.0008). The UCEIS accurately reflects clinical outcomes and predicts the medium- to long-term prognosis in UC patients undergoing induction therapy. These findings should support decision-making in clinical practice settings.

8 December 2006 in Journal of Gastroenterology
Verified
Journal Article
Open access
PDF file
HIHirohiko Iwasaki
Hirohiko Iwasaki
MKMasayoshi Kajimura
Masayoshi Kajimura
SOSatoshi Osawa
Satoshi Osawa
SKShigeru Kanaoka
Shigeru Kanaoka
TFTakahisa Furuta
Takahisa Furuta
AHAkira Hishida
Akira Hishida
Gastrointestinal motility is impaired in patients with diabetes mellitus (DM). Interstitial cells of Cajal (ICC) in the gastrointestinal tract play a central role in gastrointestinal motility. The present study examined whether ICC density, or expression of neuronal nitric oxide synthase (nNOS)- and substance P (SP)-containing nerves in the gastric antrum, were altered in patients with type 2 DM.

21 August 2019 in Digestion
Verified
Journal Article
Closed access
PDF file
TFTakahisa Furuta
Takahisa Furuta
MYMihoko Yamade
Mihoko Yamade
TKTakuma Kagami
Takuma Kagami
TUTakahiro Uotani
Takahiro Uotani
TSTakahiro Suzuki
Takahiro Suzuki
KSKen Sugimoto
Ken Sugimoto
Backgrounds/Aims: Vonoprazan (VPZ) is the first clinically available potassium competitive acid blocker. This class of agents provides faster and more potent acid inhibition than proton pump inhibitors. Most strains of Helicobacter pylori are sensitive to amoxicillin. We hypothesized that dual therapy with VPZ and amoxicillin would provide the sufficient eradication rate for H. pylori infection. To evaluate this, we compared the eradication rate by the dual VPZ/amoxicillin therapy with that by the standard triple VPZ/amoxicillin/clarithromycin therapy. Methods: Non-inferiority of the eradication rate of H. pylori by the dual therapy with VPZ 20 mg twice daily (bid) and amoxicillin 500 mg 3 times daily (tid) for 1 week to that by the triple therapy with VPZ 20 mg bid, amoxicillin 750 mg bid and clarithromycin 200 mg bid for 1 week was retrospectively studied. Propensity score matching was performed to improve comparability between 2 regimen groups. Successful eradication was diagnosed using the [13C]-urea breath test at 1–2 months after the end of eradication therapy. Results: The intention-to-treat analysis demonstrated that the eradication rate by the dual therapy (92.9%; 95% CI 82.7–98.0%, 52/56) was not inferior to that of the triple therapy (91.9%; 95% CI 80.4–97.0%, 51/56; OR 1.275, 95% CI 0.324–5.017%, p = 0.728). There were no statistically significant differences in incidences of adverse events between 2 regimens. Conclusion: VPZ-based dual therapy (VPZ 20 mg bid and amoxicillin 500 mg tid for 1 week) provides an acceptable eradication rate of H. pylori infection without the need for second antimicrobial agents, such as clarithromycin.

9 August 2016 in Immunology
Verified
Journal Article
Open access
PDF file
SOShinji Oishi
Shinji Oishi
RTRyosuke Takano
Ryosuke Takano
STSatoshi Tamura
Satoshi Tamura
STShinya Tani
Shinya Tani
MIMoriya Iwaizumi
Moriya Iwaizumi
KSKEN SUGIMOTO
KEN SUGIMOTO
Summary: Bone‐marrow‐derived macrophages are divided into two phenotypically and functionally distinct subsets, M1 and M2 macrophages. Recently, it was shown that adoptive transfer of M2‐polarized peritoneal macrophages reduced the severity of experimental colitis in mice. However, it is still unclear whether peritoneal macrophages possess the same ability to be polarized to cells with functionally different phenotypes and cytokine production patterns as bone‐marrow‐derived macrophages. To address this question, we examined the ability of peritoneal macrophages to be polarized to the M1 and M2 phenotypes and determined the specific cytokine profiles of cells with each phenotype. We showed that peritoneal macrophages, as well as bone‐marrow‐derived macrophages, were differentiated into M1 and M2 phenotypes following stimulation with interferon‐γ (IFN‐γ) and interleukin‐4 (IL‐4)/IL‐13, respectively. Following in vitro stimulation with lipopolysaccharide, M2‐polarized peritoneal macrophages predominantly expressed T helper type 2 (Th2) cytokines and regulatory cytokines, including IL‐4, IL‐13, transforming growth factor‐β and IL‐10, whereas M1‐polarized peritoneal macrophages expressed negligible amounts of Th1 and pro‐inflammatory cytokines. ELISA showed that M2‐polarized peritoneal macrophages produced significantly more IL‐10 than M1‐polarized peritoneal macrophages. Notably, M2‐polarized peritoneal macrophages contributed more to the suppression of T‐cell proliferation than did M1‐polarized peritoneal macrophages. The mRNA expression of Th2 cytokines, including IL‐4 and IL‐13, increased in T‐cells co‐cultured with M2‐polarized macrophages. Hence, our findings showed that M2 polarization of peritoneal macrophages induced regulatory cytokine production and suppressed T‐cell proliferation in vitro, and that resident peritoneal macrophages could be used as a new adoptive transfer therapy for autoimmune/inflammatory diseases after polarization to the regulatory phenotype ex vivo.

16 September 2013 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
SSS. Sahara
S. Sahara
MSM. Sugimoto
M. Sugimoto
TUT. Uotani
T. Uotani
HIH. Ichikawa
H. Ichikawa
MYM. Yamade
M. Yamade
TFT. Furuta
T. Furuta
Background Twice‐daily dosing of proton pump inhibitors (PPIs) is used to treat Helicobacter pylori or acid‐related diseases, such as gastro‐oesophageal reflux disease (GERD) refractory to standard dose of a PPI. Genetic polymorphisms of CYP2C19 are involved to different extents in the metabolism of four kinds of PPIs (omeprazole, lansoprazole, rabeprazole and esomeprazole) available in Japan. Aim To compare acid‐inhibitory effects of the four PPIs dosed twice daily in relation to CYP2C19 genotype. Methods We performed 24‐h pH monitoring studies on Day 7 of PPI treatment for 40 Japanese H. pylori‐negative volunteers [15 CYP2C19 rapid metabolisers (RMs), 15 intermediate metabolisers (IMs) and 10 poor metabolisers (PMs)] using a randomised four‐way crossover design: omeprazole 20 mg, esomeprazole 20 mg, lansoprazole 30 mg and rabeprazole 10 mg twice daily. Results Although median pH values with esomeprazole, omeprazole, lansoprazole and rabeprazole were 5.7 (3.5–7.2), 5.5 (2.4–7.2), 5.5 (3.7–7.3) and 5.2 (2.5–7.3), respectively (no statistically significant differences), CYP2C19 genotype‐dependent differences were smaller for esomeprazole and rabeprazole compared with values for omeprazole and lansoprazole. In CYP2C19 RMs, the median pH with esomeprazole [5.4 (3.5–6.8)] was significantly higher than those with omeprazole [5.0 (2.4–5.9), P = 0.018], lansoprazole [4.7 (3.7‐5.5), P = 0.017] or rabeprazole [4.8 (2.5–6.4), P = 0.002]. In IMs and PMs, the median pH was >5.0 independent of the PPI. Conclusions In intermediate and rapid metabolisers of CYP2C19, PPIs dosed twice daily could attain sufficient acid suppression, while in CYP2C19 RMs, esomeprazole 20 mg twice daily caused the strongest inhibition of the four PPIs. Therefore, esomeprazole may be effective in Japanese population when dosed twice daily.